http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Yuesong Pan (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Yuesong Pan,Zixiao Li,Jiejie Li,Aoming Jin,Jinxi Lin,Jing Jing,Hao Li,Xia Meng,Yilong Wang,Yongjun Wang 대한뇌졸중학회 2021 Journal of stroke Vol.23 No.1
Background and Purpose: Despite administration of evidence-based therapies, residual risk of stroke recurrence persists. This study aimed to evaluate the residual risk of recurrent stroke in acute ischemic stroke or transient ischemic attack (TIA) with adherence to guideline-based secondary stroke prevention and identify the risk factors of the residual risk. Methods: Patients with acute ischemic stroke or TIA within 7 hours were enrolled from 169 hospitals in Third China National Stroke Registry (CNSR-III) in China. Adherence to guideline-based secondary stroke prevention was defined as persistently receiving all of the five secondary prevention medications (antithrombotic, antidiabetic and antihypertensive agents, statin and anticoagulants) during hospitalization, at discharge, at 3, 6, and 12 months if eligible. The primary outcome was a new stroke at 12 months. Results: Among 9,022 included patients (median age 63.0 years and 31.7% female), 3,146 (34.9%) were identified as adherence to guideline-based secondary prevention. Of all, 864 (9.6%) patients had recurrent stroke at 12 months, and the residual risk in patients with adherence to guidelinebased secondary prevention was 8.3%. Compared with those without adherence, patients with adherence to guideline-based secondary prevention had lower rate of recurrent stroke (hazard ratio, 0.85; 95% confidence interval, 0.74 to 0.99; P=0.04) at 12 months. Female, history of stroke, interleukin- 6 ≥5.63 ng/L, and relevant intracranial artery stenosis were independent risk factors of the residual risk. Conclusions: There was still a substantial residual risk of 12-month recurrent stroke even in patients with persistent adherence to guideline-based secondary stroke prevention. Future research should focus on efforts to reduce the residual risk.
-
Weihua Jia,Lichun Zhou,Xiaoling Liao,Yuesong Pan,Yongjun Wang 대한신경과학회 2015 Journal of Clinical Neurology Vol.11 No.4
Background and Purpose It is unclear whether postthrombolytic antiplatelet (AP) therapy after thrombolytic-related hemorrhage without extensive parenchymal involvement (THEPI) afects the clinical outcome. Tis study explored whether AP administration in patients with THEPI afects short- and long-term outcomes. Methods All of the data for this study were collected from the Trombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China) registry. Patients with THEPI were assigned to either the AP (AP therapy should be commenced 24 h afer intravenous thrombolysis) or AP-naïve groups. THEPI was defned according to European-Australasian Acute Stroke Study II criteria. Te 90-day functional outcome, 7-day National Institutes of Health Stroke Scale (NIHSS) score, and 7-day and 90-day mortalities were compared between the AP and AP-naïve groups. Logistic regression analysis was used to evaluate the effects of AP therapy on the short- and long-term clinical outcomes. Results Of the 928 patients enrolled from those in the TIMS-China registry (n=1,440), 89 (9.6%) had nonsymptomatic intracerebral hemorrhage (ICH) within 24–36 h afer thrombolysis; 33 (37%) of these patients were given AP therapy (AP group) and 56 (63%) were not (APnaïve group). No significant differences were found for the risk of 7-day aggravated ICH (p=0.998), 7-day NIHSS score (p=0.5491), 7-day mortality [odds ratio (OR)=3.427; 95% confdence interval (95% CI)=0.344–34.160; p=0.294], 90-day mortality (OR=0.788, 95% CI=0.154– 4.040, p=0.775), or modifed Rankin score 5 or 6 at 90-days (OR=1.108, 95% CI=0.249–4.928, p=0.893) between the AP and AP-naïve groups afer THEPI. Conclusions Early administration of postthrombolytic AP therapy afer THEPI does not worsen either the short- or long-term outcome. AP therapy may be a reasonable treatment option for patients with THEPI to reduce the risk of ischemic stroke recurrence.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
